Postural Orthostatic Tachycardia Syndrome (POTS) Diagnostic Criteria and Evaluation

Core Diagnostic Criteria

• The American College of Cardiology recommends diagnosing POTS by demonstrating a sustained heart rate increase of ≥30 bpm (≥40 bpm in adolescents aged 12-19 years) within 10 minutes of standing, in the absence of orthostatic hypotension, accompanied by symptoms of orthostatic intolerance 1
• The standing heart rate often exceeds 120 bpm in affected patients, and orthostatic hypotension must be explicitly ruled out—defined as a systolic BP drop ≥20 mmHg or diastolic BP drop ≥10 mmHg within 3 minutes of standing 1

Characteristic Symptoms to Evaluate

• Patients with POTS present with a constellation of symptoms that typically worsen upon standing and improve when sitting or lying down, including dizziness and light-headedness, palpitations and sinus tachycardia, generalized weakness, fatigue, and lethargy, tremor, visual disturbances, cognitive difficulties, headache, chest pain, and gastrointestinal dysfunction 1, 2

Initial Diagnostic Testing Protocol

• The 10-minute active stand test with continuous monitoring is the first-line diagnostic approach, which involves measuring blood pressure and heart rate after 5 minutes of lying supine, and then recording immediately upon standing, then at 2, 5, and 10 minutes after standing 1
• The patient must stand quietly for the full 10 minutes, and document all symptoms that occur during the test, in a quiet environment with temperature controlled between 21-23°C, after fasting for 3 hours, and avoiding nicotine, caffeine, theine, or taurine-containing drinks on the day of examination 1

Essential Laboratory and Cardiac Workup

• A 12-lead ECG is mandatory to rule out arrhythmias or conduction abnormalities, and thyroid function tests are necessary to exclude hyperthyroidism 1
• A detailed medical history, including family history of similar conditions, and a comprehensive medication review, especially cardioactive drugs, are required 1

Additional Testing for Comorbid Conditions

• When POTS is confirmed, evaluate for commonly associated conditions, including mast cell activation syndrome (MCAS), celiac disease, gastric motor function testing, and pelvic floor dysfunction, using tests such as serum tryptase levels, gastric emptying, and anorectal manometry 2

Common Diagnostic Pitfalls to Avoid

• Failing to perform the full 10-minute stand test may miss delayed heart rate increases, and not distinguishing POTS from inappropriate sinus tachycardia or other tachyarrhythmias can lead to misdiagnosis 1, 3
• Testing under improper conditions, such as not fasting, caffeine intake, or wrong temperature, can affect results and lead to misdiagnosis 1

Associated Conditions to Screen For

• POTS frequently coexists with deconditioning, chronic fatigue syndrome, joint hypermobility syndrome, post-viral syndromes, depression, and anxiety, and targeted screening for mental health issues is reasonable 1, 3, 4

POTS Diagnostic Approach

Initial Evaluation and Testing

• The American Gastroenterological Association recommends autonomic function testing, including tilt table or sudomotor testing, for atypical POTS cases 5
• Autoantibody testing should be considered if POTS is confirmed, as recommended by the Clinical Gastroenterology and Hepatology society 5

Screening for Comorbid Conditions

• The American Gastroenterological Association suggests evaluating for Mast Cell Activation Syndrome (MCAS) by obtaining baseline serum tryptase level and collecting tryptase levels at baseline and 1-4 hours following symptom flares, with a diagnostic threshold of increase of 20% above baseline plus 2 ng/mL 5, 6
• Celiac disease testing should be considered earlier in patients with hypermobile Ehlers-Danlos syndrome (hEDS)/Hypermobile Spectrum Disorder (HSD) and various gastrointestinal symptoms, as recommended by the Clinical Gastroenterology and Hepatology society 6
• Gastric motor function testing, such as gastric emptying and/or accommodation, should be considered in patients with chronic upper gastrointestinal symptoms, as abnormal gastric emptying may be more common than in the general population 6
• Anorectal manometry, balloon expulsion test, or defecography should be considered for incomplete evacuation symptoms, given the high prevalence of pelvic floor dysfunction 5, 6
• Joint hypermobility syndrome/hypermobile Ehlers-Danlos syndrome should be screened for, as recommended by the Clinical Gastroenterology and Hepatology society 5, 6

Diagnostic Approach for Postural Orthostatic Tachycardia Syndrome (POTS)

Diagnostic Criteria and Testing Protocol

• The European Society of Cardiology recommends that POTS can only be diagnosed in the absence of orthostatic hypotension, which must be explicitly ruled out—defined as a systolic BP drop ≥20 mmHg or diastolic BP drop ≥10 mmHg within 3 minutes of standing 7
• Critical testing conditions to avoid false results include a quiet environment with temperature controlled between 21-23°C, patient fasted for 3 hours before the test, and avoidance of nicotine, caffeine, theine, or taurine-containing drinks on the day of examination 7

Autonomic Function Testing

• Autonomic function assessment should be performed in a dedicated laboratory by a specialist trained in autonomic function testing, including beat-to-beat BP and ECG monitoring, tilt table testing, Valsalva maneuver, and 24-hour ambulatory BP monitoring 7
• The Valsalva maneuver is a useful test in autonomic function assessment 8
• No single autonomic function test can provide comprehensive assessment, so different clinical questions may require different batteries of tests 7

Laboratory and Ancillary Testing Recommendations for Suspected POTS

Autoimmune Evaluation

• In patients with a confirmed diagnosis of postural tachycardia syndrome (POTS), clinicians should consider ordering auto‑antibody panels when an autoimmune mechanism is suspected, such as in post‑viral presentations. 9

Mast Cell Activation Syndrome (MCAS) Assessment

• When clinical features suggest mast‑cell activation (multisystem symptoms or allergy‑like manifestations), obtain a baseline serum tryptase level. 9
• For the same patients, repeat tryptase measurement 1–4 hours after a symptom flare to capture dynamic changes. 9
• A diagnostic rise in tryptase is defined as an increase of ≥20 % above the baseline value and an absolute increase of at least 2 ng/mL. 9
• These tryptase evaluations should be limited to individuals with an appropriate history of suspected MCAS and are not recommended for all POTS patients. 9

Condition‑Specific Testing

• In patients presenting with gastrointestinal complaints and joint hypermobility, screen for celiac disease using serologic testing. 9
• For patients in whom a hypovolemic POTS phenotype is suspected, assess iron status (e.g., ferritin, transferrin saturation) to identify contributing iron deficiency. (Evidence level not specified)
• Conduct a clinical Beighton score assessment to identify joint hypermobility syndrome, which may influence management decisions. 9

Tests to Avoid Routinely

• Comprehensive autonomic function testing (beat‑to‑beat blood pressure monitoring, Valsalva maneuver, sudomotor testing) should be reserved for atypical cases or when the diagnosis remains uncertain after initial evaluation. 9
• Mast‑cell staining of endoscopic biopsies lacks validated clinical utility for isolated gastrointestinal symptoms without systemic mast‑cell disease and should not be performed routinely. 9
• Extensive food‑allergy panels are not supported by current evidence in the evaluation of POTS and should be avoided. 9
• Ordering broad autoimmune panels without specific clinical indication can lead to unnecessary resource use and false‑positive results that may complicate management. 9
• Universal tryptase testing in all POTS patients is not evidence‑based; it should be limited to those with multisystem symptoms suggestive of mast‑cell activation. 9

Medication Review

• A thorough medication review is mandatory for every patient with suspected POTS, focusing on cardioactive agents, diuretics, vasodilators, and negative chronotropes that could precipitate or worsen orthostatic symptoms. 10